The earnings call highlighted significant revenue growth, successful product approvals, and strong financial performance, with only a few challenges noted in manufacturing for Vaprisol. The overall sentiment is positive due to the outweighing highlights.

Company Guidance -

Q2 2025

During the Cumberland Pharmaceuticals First Quarter 2025 Financial Report and Company Update, the company reported a significant 38% increase in revenue compared to the prior year, reaching $11.7 million. Their financial position was bolstered by a $3 million milestone payment linked to the approval of their Vibativ brand in China, contributing to a net profit of $1.26 million and adjusted earnings of $2.4 million. The company's balance sheet showed $70 million in total assets, including $50 million in cash, and a reduction in debt, resulting in total liabilities of $42 million and shareholders' equity of $51 million. Additionally, Cumberland highlighted the progress of their ifetroban product candidate in a Phase II study for Duchenne muscular dystrophy, reporting a 3.3% improvement in left ventricular ejection fraction compared to placebo. They also discussed the approval of Vibativ in China, providing access to the world's second-largest pharmaceutical market, and anticipated the product's launch later in the year.

Significant Revenue Growth

Cumberland Pharmaceuticals reported a 38% increase in combined revenues for the first quarter of 2025, totaling $11.7 million.

Milestone Payment for Vibativ

A $3 million milestone payment was received for the approval of the Vibativ brand in China, contributing to the company's revenue growth.

Positive Phase II Results for Ifetroban

Announced successful top-line results from a Phase II study for ifetroban in patients with Duchenne muscular dystrophy, marking a breakthrough for cardiac complications in these patients.

Expansion in China Market

Approval of Vibativ in China, opening access to the world's second-largest pharmaceutical market.

Strong Balance Sheet

Improved balance sheet with $70 million in total assets, $50 million in cash, and total liabilities reduced to $42 million, resulting in shareholders' equity of $51 million.

Positive Net Profit and Cash Flow

Reported a net profit of $1.26 million and adjusted earnings of $2.4 million, with cash flow from operations at $3.9 million.

Cumberland Pharmaceuticals (CPIX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CPIX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2025	2025 (Q2)	- / -	-0.077	―	―	―
May 06, 2025	2025 (Q1)	- / 0.08	-0.138	159.42% (+0.22)	―
Mar 04, 2025	2024 (Q4)	- / -0.14	-0.444	69.37% (+0.31)	―
Nov 07, 2024	2024 (Q3)	- / -0.11	-0.074	-48.65% (-0.04)	―
Aug 06, 2024	2024 (Q2)	- / -0.08	0.06	-228.33% (-0.14)	―
May 07, 2024	2024 (Q1)	- / -0.14	0.013	-1161.54% (-0.15)	―
Mar 05, 2024	2023 (Q4)	- / -0.44	-0.17	-161.18% (-0.27)	―
Nov 07, 2023	2023 (Q3)	- / -0.07	-0.03	-146.67% (-0.04)	―
Aug 08, 2023	2023 (Q2)	- / 0.06	-0.09	166.67% (+0.15)	―
May 09, 2023	2023 (Q1)	- / 0.01	-0.09	114.44% (+0.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CPIX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 06, 2025	$4.41	$4.42	+0.23%
Mar 04, 2025	$6.05	$6.77	+11.90%
Nov 07, 2024	$1.20	$1.19	-0.83%
Aug 06, 2024	$1.50	$1.48	-1.33%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cumberland Pharmaceuticals Inc (CPIX) report earnings?

Cumberland Pharmaceuticals Inc (CPIX) is schdueled to report earning on Aug 12, 2025, After Close (Confirmed).

What is Cumberland Pharmaceuticals Inc (CPIX) earnings time?

Cumberland Pharmaceuticals Inc (CPIX) earnings time is at Aug 12, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CPIX EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing